BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6369001)

  • 1. [Dopaminergic agents in the treatment of hyperprolactinemia].
    Mornex R; Hugues B
    J Pharmacol; 1983; 14 Suppl 3():81-103. PubMed ID: 6369001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pathophysiology of hyperprolactinemic states and the role of newer ergot compounds in their treatment.
    Frantz AG; Kleinberg DL
    Fed Proc; 1978 Jun; 37(8):2192-7. PubMed ID: 26606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hyperprolactinemia].
    König MP; Kopp P
    Schweiz Med Wochenschr; 1986 Mar; 116(9):265-70. PubMed ID: 3952483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperprolactinemia and hypogonadism in the human female.
    Rolland R; Corbey RS
    Eur J Obstet Gynecol Reprod Biol; 1977; 7(5):337-48. PubMed ID: 400856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
    Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromocriptine for induction of ovulation in hyperprolactinemic amenorrhea.
    Nillius SJ
    Acta Eur Fertil; 1984; 15(2):83-91. PubMed ID: 6475464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic mediation of beta-endorphin-induced prolactin secretion.
    Van Loon GR; De Souza EB; Shin SH
    Neuroendocrinology; 1980 Oct; 31(4):293-6. PubMed ID: 6252497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic evaluation of hyperprolactinemia.
    Biller BM
    J Reprod Med; 1999 Dec; 44(12 Suppl):1095-9. PubMed ID: 10649817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs that affect the breast and lactation.
    Dickey RP; Stone SC
    Clin Obstet Gynecol; 1975 Jun; 18(2):95-111. PubMed ID: 1095275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of psychotropic-induced hyperprolactinemia.
    Marken PA; Haykal RF; Fisher JN
    Clin Pharm; 1992 Oct; 11(10):851-6. PubMed ID: 1341991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B; Nesher Y; Barziliai S
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between hypothalamic and peripheral hormones in the control of prolactin secretion.
    Ferland L; Labrie F; Kelly PA; Raymond V
    Fed Proc; 1980 Sep; 39(11):2917-22. PubMed ID: 7409210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic control of prolactin secretion.
    Flückiger E
    Bull Schweiz Akad Med Wiss; 1978 Mar; 34(1-3):191-6. PubMed ID: 27267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of phospholipid turnover and prolactin release in a dopamine-sensitive, prolactin-secreting rat pituitary adenoma and in two dopamine-resistant, prolactin-secreting rat pituitary tumors.
    Forget H; Huot C; Collu R
    J Neuroendocrinol; 1990 Dec; 2(6):833-8. PubMed ID: 19215426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic stimulation of prolactin release.
    Denef C; Manet D; Dewals R
    Nature; 1980 May; 285(5762):243-6. PubMed ID: 6154895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
    Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
    Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin and growth hormone responses in the amenorrhea-galactorrhea syndrome.
    Hagen TC; Sill AJ; Garthwaite TL; Halverson G; Borkowf HI
    Obstet Gynecol; 1980 Aug; 56(2):204-7. PubMed ID: 7190256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
    Nickelsen T; Jungmann E; Althoff P; Schumm-Draeger PM; Usadel KH
    Arzneimittelforschung; 1993 Apr; 43(4):421-5. PubMed ID: 8098604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cimetidine and hyperprolactinemia].
    Morosini PP; Campanella N; Ghirelli S; Pellegrini F; Testa I; De Martinis C
    Boll Soc Ital Biol Sper; 1979 Jan; 55(1):14-7. PubMed ID: 551779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Possible mechanisms of the interaction between gonadotropins and prolactin in an experimental hyperprolactinemia model].
    Tresguerres JA; Esquifino AI
    Acta Physiol Lat Am; 1983; 33(3):257-74. PubMed ID: 6424409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.